VEGFR-2 was found to play a key role in EGFR-TKI resistance and the combinatory use of Erlotinib with a VEGFR-2 inhibitor showed therapeutic promise for NSCLC patients with EGFR mutations. Here, KDR is linked to non-small cell lung carcinoma.